Shire/Avexa Expand Agreement On HIV Candidate Apricitabine
This article was originally published in The Pink Sheet Daily
Acquisition of North American marketing rights to the novel nucleoside reverse transcriptase inhibitor gives Australian biotech Avexa worldwide commercialization rights.
You may also be interested in...
GSK also initiates price increase for its HIV drugs.
Agreement with Medivir and in-house development of two inhibitors could add to Bristol’s HIV stable.
The company will continue to supply zalcitabine, one of the first nucleoside reverse transcriptase inhibitors, through the end of the year.